RENO, Nev., Aug. 6, 2012 /PRNewswire/ -- First Warning
Systems, Inc. announces members of the Reno Angels have joined
together with local investors to invest in the First Warning
Systems $1,000,000 Series A funding
round.
Jim Holmes, First Warning's CEO
states, "We are approaching fifty percent completion of this Series
A round of financing. We appreciate members of the Reno
Angels and local investors' support of the First Warning
System."
For particulars concerning the Series A round, please check
First Warning's website:
www.firstwarningsystems.com/series-a-funding.html.
The First Warning patented technology uses predictive analytics
software to penetrate imaging technology barriers that are limited
to viewing a tumor that, on average, has been growing for 11
years. Deep tissue temperature analysis from 12 hours of
dynamic data collection is modeled using predictive analytics
software to compare circadian body rhythms that can identify
abnormalities up to 6 years prior to imaging technologies. The
First Warning product vision video can be seen at
www.firstwarningsystems.com
Holmes adds, "We are planning the establishment of a production
facility for our products, determining employee requirements to
support worldwide marketing and sales. We are investigating
and hopeful of being able to establish these operations in the
Truckee Meadows
area."
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in
Reno, NV. FWS' principal
shareholder is Lifeline Biotechnologies, Inc. (OTC Market: LLBO).
FWS holds the exclusive worldwide license from Lifeline
Biotechnologies for development, manufacturing and marketing of the
software-based technologies. The FWS product line is a patented
device and process that detects breast tissue abnormalities for
health risk assessment and management earlier than any other known
modalities. These tissue abnormalities can lead to breast
cancers. Three clinical trials with over 650 participants have
achieved proof of concept and superior outcomes with industry
leading 90% accuracy. FWS is planning a final, limited
clinical trial and a 510k device classification to validate the
fourth generation of the FWS predictive analytics product.
FWS is preparing for Euro CE Mark and marketing in the UK, EU and
Russian markets. For more information check
www.firstwarningsystems.com
For more information, contact: Jim Holmes, CEO 775-324-3822 or 775-852-3222,
jholmes@firstwarningsystems.com
SOURCE First Warning Systems, Inc.